Darmstadt, Germany 7/15/10—Merck KGaA has announced the closing of its acquisition of Millipore for $7.0 billion (see IBO 3/15/10). The new company will be named Merck Millipore and will consist of three business units: Bioscience, Lab Solutions and Process Solutions. Headquartered in Billerica, Massachusetts, with 10,000 employees, Merck Millipore had 2009 pro forma revenues of $2.9 billion. “We will now move quickly to bring together the expertise and complementary capabilities of both Merck and Millipore employees to capture the significant opportunities in the high-growth, high-margin market segments such as bio-research and bio-production,” stated Dr. Karl-Ludwig Kley, chairman of the Merck Executive Board. Merck Chemicals Head Dr. Bernd Reckmann will lead Merck Millipore. Jon DiVincenzo, president of Millipore’s Bioscience division, will lead the Bioscience business; Klaus R. Bischoff, president of Merck Performance & Life Science Chemicals, will lead the Lab Solutions business; and Jean-Paul Mangeolle, president of Millipore’s Bioprocess division, will head the Process Solutions Business. Millipore CEO Martin Madaus will be available as an advisor during the integration process. The majority of the integration decisions are expected to be made by year end and to generate annual cost synergies of $100 million within three years.